Nature Reviews Gastroenterology & Hepatology, Published online: 29 September 2025; doi:10.1038/s41575-025-01107-2Portal hypertension and systemic inflammation are key factors driving decompensation and organ failure in cirrhosis. This Review examines those two factors and, based on their mechanistic interaction, proposes a new concept of the clinical phenotypes in decompensated cirrhosis.

Fue el primer director científico del Ciber de Enfermedades Hepáticas y Digestivas

A giant in both humanity and science, Jaume was an extraordinary mentor and role model to countless physicians and researchers […]

There is no evidence of a difference between carvedilol 12.5 mg daily and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium-to large-sized oesophageal varices. ....

Previous studies suggested that anticoagulation decreases the probability of developing portal hypertension (PHT)-related complications and improves survival in cirrhotic patients. Our study aimed to ...

This paper is more than a review: it is a consensus report by a group of 34 leading international experts in hepatology, data science, and artificial intelligen